SCHEMBL24071510

SCHEMBL24071510

CC(=O)N1CCCC(C(=O)Nc2nc3c(F)cc(F)cc3s2)C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.67
▸ RAB9A P51151 7/20 0.67
▸ MAPK8 P45983 4/20 0.49
▸ MAPK10 P53779 4/20 0.49
▸ MAPK14 Q16539 4/20 0.49
▸ MAPT P10636 5/20 0.49
▸ POLB P06746 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ PKM P14618 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ CHKA P35790 1/20 0.48
▸ LMNA P02545 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ AGTR1 P30556 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24071446 0.94 RAB9A (0.69) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL25199236 0.91 NPC1 (0.68) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL25197014 0.91 NPC1 (0.68) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071501 0.90 NPC1 (0.70) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071507 0.90 NPC1 (0.67) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071505 0.89 NPC1 (0.63) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071592 0.88 RAB9A (0.69) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071464 0.87 NPC1 (0.76) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL24071502 0.87 NPC1 (0.62) NPC1RAB9AMAPTPOLBALDH1A1
SCHEMBL31389071 0.87 NPC1 (0.62) NPC1RAB9AMAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203025-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A Sanford Burnham Prebys Medical Discovery Institute 2023-06-29 — — US disclosed
US-20230203025-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A Sanford Burnham Prebys Medical Discovery Institute 2023-06-29 — — US disclosed
WO-2021243230-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203025-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A GPR119, GUCY1A2, PRKG1 NPC1 224/4885RAB9A 1329/4885MAPK8 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback